• Cytokinetics annual report for fiscal 2025 highlighted FDA clearance in December 2025 for MYQORZO (aficamten) in adults with symptomatic obstructive hypertrophic cardiomyopathy, marking company transition to commercial-stage operations.
• Global footprint expanded with China authorization in 2025 for adult NYHA class II-III obstructive HCM, followed by European Commission authorization in February 2026 for adult NYHA class II-III obstructive HCM.
• US launch began in first quarter 2026, with product available for prescription around January 27, 2026.
• Pipeline progress included positive Phase 3 MAPLE-HCM results versus metoprolol, with supplemental NDA submitted to FDA in January 2026 and potential decision expected in fourth quarter 2026.
• Development catalysts include Phase 3 ACACIA-HCM in non-obstructive HCM with top-line results expected in Q2 2026, alongside ongoing COMET-HF Phase 3 omecamtiv mecarbil enrollment and AMBER-HFpEF Phase 2 ulacamten enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief on April 17, 2026, and is solely responsible for the information contained therein.